Exclusive | How Replimune’s Drug Got Third Chance After White House Intervention - WSJ
Exclusive | How Replimune’s Drug Got Third Chance After White House Intervention WSJ Replimune Gets Third Try at FDA Approval After Makary Departure WSJ Replimune to resubmit twice-rejected drug for approval after FDA shakeup CNBC REPL Stock Shot Up 80% Today – What’s The Deal With FDA? Yahoo Finance Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks BioPharma Dive
YesNo saves this item as an on-site live signal so search users can understand how it connects to prediction markets and incubation topics.
If later reporting creates a clear deadline, official source, or verifiable outcome, the public event can become a tradable Yes/No question.
This item has a verifiable event angle that can be monitored for a Yes/No prediction market.